3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Expanded_access
1
Sponsor
Cancer Type
Thoracic
3
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Oxaliplatin
1409
Fluorouracil
1298
Capecitabine
1085
Gemcitabine
1042
Leucovorin
928
Irinotecan
815
Bevacizumab
803
Cisplatin
666
Radiotherapy
535
Cetuximab
469
pembrolizumab
428
Paclitaxel
389
Nivolumab
336
130-nm albumin-bound paclitaxel
322
Drug Therapy
314
Docetaxel
286
S 1 (combination)
273
Sorafenib
266
Folfox protocol
261
Albumin-Bound Paclitaxel
259
sintilimab
211
durvalumab
209
Surgical Procedures, Operative
203
tislelizumab
202
Radiosurgery
202
lenvatinib
201
apatinib
198
Carboplatin
186
Magnetic Resonance Spectroscopy
181
regorafenib
180
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
AM0010
×
Gastrointestinal
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled
NCT02923921
2020-10-19
Sequoia
Eli Lilly and Company
Phase 3
Completed
567 enrolled
17 charts